JP2012505257A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505257A5
JP2012505257A5 JP2011531261A JP2011531261A JP2012505257A5 JP 2012505257 A5 JP2012505257 A5 JP 2012505257A5 JP 2011531261 A JP2011531261 A JP 2011531261A JP 2011531261 A JP2011531261 A JP 2011531261A JP 2012505257 A5 JP2012505257 A5 JP 2012505257A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
hydrogen
use according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011531261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060557 external-priority patent/WO2010045265A1/en
Publication of JP2012505257A publication Critical patent/JP2012505257A/ja
Publication of JP2012505257A5 publication Critical patent/JP2012505257A5/ja
Pending legal-status Critical Current

Links

JP2011531261A 2008-10-13 2009-10-13 多発性硬化症治療のための組成物および方法 Pending JP2012505257A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10485408P 2008-10-13 2008-10-13
US61/104,854 2008-10-13
US15768709P 2009-03-05 2009-03-05
US61/157,687 2009-03-05
PCT/US2009/060557 WO2010045265A1 (en) 2008-10-13 2009-10-13 Compositions and methods for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2012505257A JP2012505257A (ja) 2012-03-01
JP2012505257A5 true JP2012505257A5 (https=) 2012-11-08

Family

ID=42106858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531261A Pending JP2012505257A (ja) 2008-10-13 2009-10-13 多発性硬化症治療のための組成物および方法

Country Status (4)

Country Link
US (2) US20110195049A1 (https=)
EP (1) EP2355660A4 (https=)
JP (1) JP2012505257A (https=)
WO (1) WO2010045265A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340254B8 (en) 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
US8545892B2 (en) * 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
NO2665471T3 (https=) 2011-01-19 2018-05-26
AU2012286701A1 (en) * 2011-07-28 2014-03-06 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
KR101778169B1 (ko) * 2012-04-11 2017-09-13 리폭센 테크놀로지즈 리미티드 미엘린염기성단백질의 올리고펩티드 단편을 함유하는 리포솜, 의약조성물 및 다발성경화증의 치료법
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
CN109432073A (zh) * 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
JP2018504454A (ja) 2015-01-12 2018-02-15 ナノ ファーマシューティカル ラボラトリーズ エルエルシーＮａｎｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌａｂｏｒａｔｏｒｉｅｓ ＬＬＣ 積層徐放型マイクロビーズ及びその作製方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US20050065219A1 (en) * 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
KR20080034171A (ko) * 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
EP2021327B1 (en) * 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JP2010504338A (ja) * 2006-09-20 2010-02-12 メディベイション ニューロロジー， インコーポレイテッド 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
MX2009012788A (es) * 2007-05-25 2010-01-14 Medivation Neurology Inc Metodos y composiciones para estimular celulas.
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions

Similar Documents

Publication Publication Date Title
JP2012505257A5 (https=)
JP2012512165A5 (https=)
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
JP2010077141A5 (https=)
RU2002129558A (ru) КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА)
JP2006514611A5 (https=)
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
JP2017518334A5 (https=)
JP2016512531A5 (https=)
RU2007126483A (ru) Гетероциклические ингибиторы аспартилпротеазы
JP2015528471A5 (https=)
JP2011524850A5 (https=)
JP2016517883A5 (https=)
CN1812812B (zh) 降血清胆固醇药或者动脉粥样硬化的预防或治疗药
CO6612204A2 (es) Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina
JP2014505108A5 (https=)
JP2010511631A5 (https=)
JP2016510785A5 (https=)
JP2012502915A5 (https=)
JP2013522368A5 (https=)
JP2009519350A5 (https=)
NZ608375A (en) Pharmaceutical combination of an mtor catalytic inhibitor and an allosteric mtor inhibitor
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
RU2019112148A (ru) Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени
JP2017509611A5 (https=)